State Action
CCAGW Urges Oklahoma Senate to Oppose HB 1602
HB 1602 will fail to achieve its objective to protect consumer privacy.
CCAGW Urges Maine Joint Committee on Health Coverage Insurance, and Financial Services to Oppose LD 675
LD 675 will not lower drug prices and could deny Maine citizens access to important medicines.
CCAGW Urges North Dakota Senate to Oppose HB 1032
CCAGW urges the North Dakota Senate to oppose drug transparency legislation, which will not lower drug costs.
CCAGW Urges Washington House of Representatives to Oppose SB 5062
SB 5062 will fail to achieve its objective to protect consumer privacy.
CCAGW urges the Arkansas House of Representatives to Oppose HB 1709
CCAGW urges the Arkansas House of Representatives to oppose a bill that would utilize price controls to determine the pricing for insulin in the state.
CCAGW Urges North Dakota House of Representatives to Oppose SB 2170
CCAGW urges the North Dakota House of Representatives to oppose legislation which adopts Canadian drug price controls.
CCAGW Urges Oregon House Health Care Committee to Oppose HB 3267
CCAGW urges Oregon House Health Care Committee to oppose price control legislation.
CCAGW Urges the North Dakota House Industry, Business, and Labor Committee to Oppose SB 2170
CCAGW urges the House Industry, Business, and Labor Committee oppose legislation which adopts Canadian drug price controls.
CCAGW Urges Oregon Senate Health Care Committee to Oppose SB 844
CCAGW urges Oregon Senate Health Care Committee to oppose price control legislation.
CCAGW Urges the Washington House Civil Rights & Judiciary Committee to Oppose SB 5062
SB 5062 will fail to achieve its objective to protect consumer privacy.
CCAGW Urges New Mexico House Judiciary Committee to Oppose SB 66
SB 66 would impose burdens on small loan lenders and force borrowers to become more dependent on government subsidies.
CCAGW Submits Testimony Opposing North Dakota HB 1032
CCAGW Submits Testimony opposing prescription drug cost transparency legislation in North Dakota.
